This page Is Inserted by IFW Operations And is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, Please do not report the images to the Image Problem Mailbox.

WHAT IS CLATMED IS:

30

50

CD40-Id.

receptor. A substantially purified confode

claim 1 which has a molecular weight of about 39 The substantially purified receptor of

The substantially purified receptor of

claim 1 which binds to/ CD40-Ig.

claim I which binds to the monoclonal antibody MRI. The substantially purified redeptor of

at least a portion of CD4¢ protein. A soluble μ igand for CD40CR, dompristing

transmembrane domain. comprises a portion of quo protein which lacks a The soluble/ligand of claim 5 which

which further comprises at least a portion of an The soluble light of claim 5 or 6

tmmunoglobulin molecule,

The soluble lighnd of claim 5 which is

at least a portion of an immunoglobulin molecule. A soluble ligand for coadcas, comprising

the immunoglobulin molecule is capable of 10. The soluble ligand/of claim b in which

CD40CK. combecifively inhibiting the binding of coad to

antibody MR: $t\phi$ its target antigen. competitively unitating the binding of mondplonat the immunoglobulth molecule is aspable of The soluble ligand of claim 9 in which

which is an antiproliferative agent. 9, 10 or 11 which/further comprises a second molecule The soluble ligand according to claim

which is an alkylating agent. 9, 10 or 11 which further comprises a second molecule 13. The spluble ligand according to claim

which is an antimetabolity $^{9},$ 10 or 11 which further comprises a second molecula 14. The soluble ligand according to claim

which is an antibiotic. 6, 10 or 11 which further comprises a second molecula 15. The soluble the dang according to olding

which is a vinca alkaloid. 9, 10 or 11 which further compatines a serond molecule The soluble lighnd according to dlaim

мріср із sn enzyme. 9, 10 or 11 which further comprises a second molecule The soluble ligand according to claim

which is a platinum coordinated complex) $_{9},$ 10 or 11 which further comprises a zecond molecule The soluble ligand according to claim

Ñ

which is a radiotsocope. 9 10 or 11 which further domprises a second molecule The soluble ligand according to claim

which is a fluorescent compound. 9, 10 or 11 which further comprises a second molepule SO. The soluble ligand according to claim

21. Mohoclonal antibody MRI or a fragment

10 thereof.

sud helper T cells th an effective concentration of scrivation comprising exposing a mixture of H-cells 22. A method of inhibiting B-cell

ligand that binds to/CD40CR.

ligand comprises at least a portion of chio protein. The method of claim 22 in which the

a transmembrane domain. ligand comprises a portiph of CD40 protein Which lacks 24. The method of claim 22 in which the

tmmunoglobulin molecule. the ligand further comprises at least a portion of an The method of claim 33 or 34 in which

ligand is CD40-Ig. se. The method of blaim 22 in which the

immunoglobulin molecule. ligand comprises at least a portion of an 27. The method of oldin 22 in which the

1. ÈŖŹſĠ

tubibiting the pinding of co40 to co40cR; rumnuodjopnjiu/wojecnje τα cabapje οι combecitively The method of claim 27 in which the

tte target antigen/ tuhibiting the bihding of monoclonal antibody MRI to immunoglobulin molecule is dapable of competitively The method of claim 27 in which the

therapeutic amount of ligand that binds to db40CR, activation, comprising administering to the Bublebt A suffering from a disorder associated with B-Dell 30. A method of treating a subject

disorder is an allergy The method of claim 30 in which the

disorder is an autoimmunh disease. 32. The method of claim 30 in which the

ligand comprises at least/a portion of cuto protein. 33. The method of claim 30 in which the

a transmembrane domain. ligand comprises a portion of cond protein which lacks 34. The method of claim 30 in which the

tmmunoglobulin molecule. the ligand further comprises at least a purtion of an 35. The method of/claim 33 or 34 in which

Ifdand is CD40-Ig. The method of claim 30 in which the

1.68278

Tigand comprises at least a portion of an immunoglobulin molecule.

the production of coape of coapetitively than the product of coapetitively the coapetitive coapetitively the coapetitive coape

39. The method of claim 37 in which the immunoglobulin molecule is dapable of competitively in this to antiborate principle of competitively antiborated of monoclonal antiboration.

15 CD40-Ig in a sultable pharmaceutical composition comprising

41. A pharmaceutical composition domprishing monoclonal antibody MRI or a rradment thereof in a sultable pharmaceutical carrier

(SABB)

• • •

Ų.

٠,

. :

Ŀ

36

I FRICE

.